At the forefront of this research is Zhu Shujia, a senior researcher at the Center for Excellence in Brain Science and Intelligence Technology of the Chinese Academy of Sciences (CAS).

　　In a recent interview at the Shanghai-based center, Zhu related how some seemingly anecdotal occurrences have helped reaffirm her faith in the societal value of her research.

　　Zhu Shujia exams a protein electrophoresis test result.  

　　She said that a couple of years ago a friend’s 70-year-old aunt did not feel her usual self, but subsequent medical checkups ruled out the possibility of any organic disease. So, the family did not feel any need for further intervention, until it was too late — the aunt took her own life. It was only in hindsight they realized that she was suffering from severe depression.

　　Zhu said that many of us undergo routine annual physical check-ups, and are declared fit in the absence of any organic abnormalities, without anyone being bothered about symptoms of depression.

　　The sad truth is that depression is one of the most common mental diseases, affecting 350 million people globally, and 95 million in China, with serious consequences: Annually some 800,000 sufferers take their own lives.

　　The action of first and second-generation anti-depressants was slow, taking at least three weeks for their effects to be felt, and with significant side effects. They proved utterly useless for 30 percent of the patients.

　　By comparison, the new generation of fast-acting antidepressant drugs can be used for treatment-resistant depression and those cases with suicidal tendencies, and can take effect in two to four hours.

　　A candidate is ketamine, which Zhu’s team has been working on, with significant progress. Once a general anesthetic and tranquilizer, it can help relieve symptoms of depression within one hour, though its drawbacks are obvious.

　　Taken in large doses it causes hallucinations, raising the problem of substance abuse. There has been a concerted medical effort to improve it and turn it into a safe drug for medical use.

　　Zhu Shujia (center) poses with her team at CAS’s Center for Excellence in Brain Science and Intelligence Technology.  

　　One of Zhu’s latest research findings was published in an article titled “Structural basis of ketamine action on human NMDA receptors” in Nature magazine in August 2021. The scientific community believes that “these findings may accelerate drug discovery efforts for novel ketamine-based antidepressants.”

　　While celebrating the acceptance of their article in June last year with her team, Zhu waxed sentimental. “This is the happiest day, but also one of the saddest. A friend of mine, who had been an alcoholic after succumbing to depression, died of severe pancreatitis. We are making progress, but we are not going fast enough,” she said.

　　As a woman scientist engaged in a field traditionally dominated by males, managing life-work balance might be thought to have posed a special challenge. Zhu said that there is no balance to speak of. There are only priorities, and sacrifices.

　　In fact, on the day she gave birth to her daughter about four years ago, she was still busy with her office work. After a two-week maternal leave, she was back in the office.

　　Zhu Shujia gives a demonstration to her students. 

　　Towards midnight one day, she got a phone call in her lab from her daughter, asking when she would be home. She was ready to go, but when she opened the door, she was greeted by three of her students waiting to discuss their research.

　　The same kind of perseverance and resilience has been manifested in Zhu’s life experience. She was born in a mountainous village in Fenghua, neighboring East China’s Zhejiang Province. After studying in Zhejiang University of Technology and then East China Normal University, she went for further studies to France and the United States, before coming to work at the center in 2016.

　　She has come a long way from that secluded village in Fenghua, but apparently she still has a long way to go.

　　Source: March 2023 SHINE 

http://newsletter.cas.cn/wap/NL197/202303/t20230329_4577442.html